PMID- 21554526
OWN - NLM
STAT- MEDLINE
DCOM- 20110811
LR  - 20220311
IS  - 1464-410X (Electronic)
IS  - 1464-4096 (Linking)
VI  - 108
IP  - 1
DP  - 2011 Jul
TI  - Safety and feasibility of the prostatic urethral lift: a novel, minimally 
      invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign 
      prostatic hyperplasia (BPH).
PG  - 82-8
LID - 10.1111/j.1464-410X.2011.10342.x [doi]
AB  - OBJECTIVES: * To investigate the Prostatic Urethral Lift (PUL) procedure, a 
      novel, minimally invasive treatment for symptomatic benign prostatic hyperplasia 
      (BPH), which aims to mechanically open the prostatic urethra without ablation or 
      resection. * To demonstrate the safety and feasibility of this procedure and to 
      make an initial assessment of effectiveness. PATIENTS AND METHODS: * The 
      PULprocedure was performed on 19 men in Australia. * Small suture-based implants 
      were implanted transurethrally under cystoscopic visualisation to separate 
      encroaching lateral prostatic lobes. * Patients were evaluated at 2 weeks and 3, 
      6, and 12 months after PUL. RESULTS: * All cases were successfully completed with 
      no serious or unexpected adverse events (AEs). * Between two and five sutures 
      were delivered in each patient and the prostatic urethral lumen was visually 
      increased in all patients. * Reported postoperative AEs were typically mild and 
      transient and included dysuria and haematuria. * Follow-up cystoscopy at 6 months 
      in a subset of patients showed no calcification. Histological findings from two 
      of three patients who progressed to transurethral resection of the prostate for 
      return of symptoms showed no evidence of inflammation related to the implanted 
      materials. * The mean International Prostate Symptom Score was reduced by 37% at 
      2 weeks and 39% at 1 year after PUL as compared with baseline. CONCLUSIONS: * We 
      demonstrated in this initial experience that the PUL procedure is safe and 
      feasible. * The safety profile of the PUL procedure appears favourable; most 
      patients reported sustained symptom relief to 12 months with minimal morbidity * 
      PUL therefore warrants further study as a new option for the many patients who 
      seek an alternative to current therapies.
CI  - (c) 2011 THE AUTHORS. BJU INTERNATIONAL (c) 2011 BJU INTERNATIONAL.
FAU - Woo, Henry H
AU  - Woo HH
AD  - Departments of Urology, University of Sydney, Sydney, NSW, Australia. 
      hwoo@urologist.net.au
FAU - Chin, Peter T
AU  - Chin PT
FAU - McNicholas, Thomas A
AU  - McNicholas TA
FAU - Gill, Harcharan S
AU  - Gill HS
FAU - Plante, Mark K
AU  - Plante MK
FAU - Bruskewitz, Reginald C
AU  - Bruskewitz RC
FAU - Roehrborn, Claus G
AU  - Roehrborn CG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110506
PL  - England
TA  - BJU Int
JT  - BJU international
JID - 100886721
SB  - IM
CIN - Nat Rev Urol. 2011 Jul;8(7):352. PMID: 21670754
CIN - Eur Urol. 2011 Nov;60(5):1120-1. PMID: 21961740
CIN - J Urol. 2012 Apr;187(4):1360. PMID: 22423934
MH  - Aged
MH  - Australia
MH  - *Cystoscopy
MH  - Feasibility Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prostatic Hyperplasia/complications/*surgery
MH  - Prostatism/etiology/*surgery
MH  - *Suture Techniques/adverse effects
MH  - Treatment Outcome
MH  - Urethra/*surgery
EDAT- 2011/05/11 06:00
MHDA- 2011/08/13 06:00
CRDT- 2011/05/11 06:00
PHST- 2011/05/11 06:00 [entrez]
PHST- 2011/05/11 06:00 [pubmed]
PHST- 2011/08/13 06:00 [medline]
AID - 10.1111/j.1464-410X.2011.10342.x [doi]
PST - ppublish
SO  - BJU Int. 2011 Jul;108(1):82-8. doi: 10.1111/j.1464-410X.2011.10342.x. Epub 2011 
      May 6.